Welcome to the Pacific Edge Investor Centre. Here you will find useful information about being a shareholder of our company.
See the latest news and presentations, keep up to date with our newsletters and shareholder reports, find out when we are holding shareholder meetings and check up on our share price.
Pacific Edge is a publicy listed company on the NZX: listed as PEB.
- Value $00,000.000
- Volume 00,000
- Capitalisation $000,000
- Open $0.000
- Close $0.000
- High $0.000
- Low $0.000
Data up to date as of 00-00-0000 00:00
Cxbladder Included in the Latest NCCN Bladder Cancer Guidelines in the USA
Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer in the USA [read more]
Clinical Study Supports Adoption of Cxbladder into New Clinical Pathway
The latest published clinical paper for Pacific Edge’s Cxbladder bladder cancer tests reveals the cementing evidence behind the introduction of new guidelines for the assessment of haematuriaby one of New Zealand’s largest public healthcare providers, Canterbury District Health Board (DHB). [read more]
Pacific Edge Reports Continued Growth in FY19
Cancer diagnostics company, Pacific Edge (NZX: PEB) has today released its audited financial results for the year ended 31 March 2019, reporting accelerating demand from new and existing customers in the second half of the financial year, particularly from New Zealand customers in the final quarter of the year. [read more]
Reports and Presentations
For further investor information on Pacific Edge our recent annual reports, investor presentations and investment research reports are available for download below
FY19 Full Year Results Presentation[8.1 MB]
FY19 Full Year Results Conference Call Audio Commentary[4.3 MB]